Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Purchases 30,884 Shares

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey bought 30,884 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were purchased at an average price of $19.54 per share, for a total transaction of $603,473.36. Following the completion of the acquisition, the director owned 981,890 shares of the company’s stock, valued at $19,186,130.60. The trade was a 3.25% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Tim Kutzkey also recently made the following trade(s):

• On Thursday, December 4th, Tim Kutzkey acquired 5,266 shares of Surrozen stock. The shares were purchased at an average price of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey acquired 315,457 shares of Surrozen stock. The stock was acquired at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Stock Performance

SRZN traded up $0.01 during trading hours on Monday, reaching $20.47. The company’s stock had a trading volume of 110,179 shares, compared to its average volume of 30,511. The company’s 50-day moving average is $13.90 and its 200-day moving average is $11.32. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $21.33. The firm has a market cap of $175.45 million, a PE ratio of -0.92 and a beta of 0.62.

Surrozen (NASDAQ:SRZN) last posted its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The company had revenue of $0.98 million for the quarter. Equities analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Surrozen

A number of hedge funds and other institutional investors have recently bought and sold shares of SRZN. Citadel Advisors LLC increased its holdings in Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares during the last quarter. Heights Capital Management Inc. acquired a new position in shares of Surrozen in the first quarter valued at approximately $524,000. Armistice Capital LLC bought a new position in Surrozen in the 2nd quarter valued at approximately $536,000. Finally, Woodline Partners LP acquired a new stake in Surrozen during the 3rd quarter worth approximately $621,000. Institutional investors own 66.57% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Wall Street Zen upgraded Surrozen to a “sell” rating in a research note on Friday, November 28th. Finally, Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.